What Are We Really Measuring in PN?

Clinical trial endpoints tell us how well a treatment can work. But what does meaningful improvement look like to the patient living with prurigo nodularis? James Q. Del Rosso, DO, explores the distinction between measurable efficacy and the changes patients actually notice, particularly relief from relentless itch, discomfort, and disrupted sleep. Using dupilumab trial endpoints as a point of comparison, he considers why a patient may experience substantial benefit even when lesion clearance falls short of a study-defined threshold, and why understanding what matters most to that patient remains essential to assessing response.